BIOMAT Database Logo BIOMAT Database Logo

Attempt made to "immunize" patients against their cancers. 1991

S Jenks

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009316 National Institutes of Health (U.S.) An operating division of the US Department of Health and Human Services. It is concerned with the overall planning, promoting, and administering of programs pertaining to health and medical research. United States National Institutes of Health,National Institutes of Health
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.

Related Publications

S Jenks
An attempt to immunize lambs against pneumonia.
December 1959, Journal of the American Veterinary Medical Association,
S Jenks
Use of dendritic cells to immunize against cancers overexpressing p53.
January 2001, Clinical cancer research : an official journal of the American Association for Cancer Research,
S Jenks
Attempts to immunize F1 hybrid mice against their parents.
August 1967, Immunology,
S Jenks
Attempt to immunize guinea pigs against leukemia by skin scarification with leukemic cell suspensions.
December 1973, Proceedings of the National Academy of Sciences of the United States of America,
S Jenks
How to Immunize Against Burnout.
January 2017, Family practice management,
S Jenks
Attempt to immunize guinea pigs against L2C leukemia with leukemia cells inactivated by gamma irradiation.
July 1979, Proceedings of the National Academy of Sciences of the United States of America,
S Jenks
An attempt to immunize sheep during an outbreak of listeriosis.
October 1951, American journal of veterinary research,
S Jenks
Attempts to immunize mice against sporotrichosis.
September 1959, The Journal of investigative dermatology,
S Jenks
Attempt to immunize a volunteer (with formalin-inactivated virus) against experimental trachoma induced by Saudi Arabian strain 2.
March 1962, Annals of the New York Academy of Sciences,
S Jenks
To immunize two cardiac patients.
June 1946, Jornal do medico,
Copied contents to your clipboard!